MagnetisMM-32
Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Elranatamab Versus Commonly Used Combination Regimens in Participants with Relapsed/Refractory Multiple Myeloma
What will happen during the trial?
Participants will be randomly assigned into either the experimental group (receiving elranatamab) or the comparator group (receiving one of three commonly used combination treatment regimens that will be selected by the study doctor). This study is open-label, which means that both researchers and participants will know which groups the participants have been placed in, and which treatments they will be receiving. Participants may continue to receive treatment as long as they don’t experience unacceptable side effects and their myeloma doesn’t get worse.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 492 patients (estimated)
- Sponsors
- Pfizer
- Tags
- Bispecific Antibody, B-Cell Maturation Antigen (BCMA), CD3
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1820
- NCT Identifier
- NCT06152575
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.